+
Site Tour

PFO closure with Amplatzer™ Talisman™ PFO Occluder in patients >60 years

An analysis was performed on real-world outcomes of U.S. Medicare beneficiaries >60 years old with presumed PFO-associated stroke implanted with the Amplatzer™ PFO Occluder or the Amplatzer™ Talisman™ PFO Occluder.

Download

Related Resources

LAAO Summit 2023: ICE

TAVI Summit - Cardiac imaging and morphology

CardioMems™

TAVI Summit - TAVR in bicuspid

Atrial Septal Defects (ASD)

EuroPCR 2023: Mitral regurgitation

PFO Patients Management: European position & Network. Dr. Sacco

LAAO Summit 2023: Anatomy & imaging – Panel

TRENDING TOPICS

EACTS 2024 - Novel approaches for Valvular and LVAD therapies

Reconsidering current approaches to valve and LVAD therapies

Early outcomes on Epic Max platform

Cleveland clinic (US) experience: Early outcomes and a perspective on porcine vs. bovine

Transfemoral TAVI

Navitor Vision 35 implantation

CONNEXT


HUB
RELATED RESOURCES

Clinical insights: PFO stroke

PDA Closure – Piccolo™

Talisman™ vs Occlutech‡ Clinical Insights

Safety and efficacy of the Trevisio™ Delivery system

CONNEXT


LIVE
RELATED EVENTS

TAVI Summit - Drive TAVI to the next level

LAAO Summit - Clinical impact of PDLs

LAAO Summit - Decoding DRT patient factors

LAAO Summit - The right antithrombotic regimen

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

OK Decline